Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report
10.9758/cpn.2022.20.3.581
- Author:
Jae Hyun RYOU
1
;
Doug Hyun HAN
;
Reeree LEE
;
Sun Mi KIM
Author Information
1. Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea
- Publication Type:Case Report
- From:Clinical Psychopharmacology and Neuroscience
2022;20(3):581-583
- CountryRepublic of Korea
- Language:English
-
Abstract:
This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that the [18F] N ‐(3‐Fluoropropyl)‐2β‐carbon ethoxy‐3β‐(4‐iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist.
